Moderna, Inc. (MRNA) Stock Grade

About Moderna, Inc.'s fundamentals

Moderna is a large-cap biotechnology company with a market capitalization of $78.3 billion, but its financial performance has deteriorated significantly. The company experienced a 39.2% year-over-year revenue decline and reported a net loss in its latest annual statement, resulting in a negative net margin of -145.2%. The company does not pay a dividend, and traditional valuation metrics like P/E ratio and return on equity are not applicable due to the loss position. This sharp reversal reflects the dramatic drop in demand for COVID-19 vaccines and therapeutics that previously drove Moderna's exceptional pandemic-era revenues.